Ethchlorvynol: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 32: | Line 32: | ||
{{stub}} | {{stub}} | ||
{{dictionary-stub1}} | {{dictionary-stub1}} | ||
<gallery> | |||
File:Ethchlorvynol_DOJ.jpg | |||
File:Ethchlorvynol_synthesis.png | |||
</gallery> | |||
Revision as of 02:08, 17 February 2025
Ethchlorvynol is a sedative and hypnotic medication developed by Pfizer in the 1950s. In the United States, it was sold under the brand name Placidyl. However, Placidyl was discontinued in 1999 due to concerns about its potential for misuse and the availability of safer alternatives.
Pharmacology
Ethchlorvynol is a member of the class of sedative-hypnotics known as chloral hydrate derivatives. It works by increasing the activity of the neurotransmitter GABA in the brain, which has a calming effect and helps to induce sleep.
Medical uses
Ethchlorvynol was primarily used to treat insomnia, but it was also used for other conditions as determined by a healthcare provider. It was typically prescribed for short-term use only, due to the risk of dependency and withdrawal symptoms with long-term use.
Side effects
Common side effects of ethchlorvynol include drowsiness, dizziness, and nausea. More serious side effects can include confusion, hallucinations, and severe allergic reactions. Long-term use can lead to dependency and withdrawal symptoms.
Abuse potential
Ethchlorvynol has a high potential for abuse and can lead to physical and psychological dependency. Withdrawal symptoms can be severe and include anxiety, restlessness, and insomnia.



